Top

Published in:

01-04-2018 | Epidemiology

Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy

Authors: Marilyn L. Kwan, Song Yao, Cecile A. Laurent, Janise M. Roh, Charles P. Quesenberry Jr., Lawrence H. Kushi, Joan C. Lo

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Abstract

Purpose

We assessed bone mineral density (BMD) change with aromatase inhibitor (AI) treatment in a contemporary cohort of women with breast cancer treated in Kaiser Permanente Northern California.

Methods

Percent and estimated annual percent changes in BMD at the total hip and lumbar spine were examined in 676 women receiving AI therapy who had two serial BMD reports available (at least 1 year apart) before and after AI initiation (N = 317) or during continued AI therapy (N = 359). BMD changes were examined at the total hip and lumbar spine and compared by age and clinical subgroups.

Results

Women experienced BMD declines after AI initiation or continued therapy, with median annual percent change − 1.2% (interquartile range, IQR − 2.4 to − 0.1%) at the hip and − 1.0% (IQR − 2.3 to 0.1%) at the spine after AI initiation, and − 1.1% (IQR − 2.4 to 0.1%) at the hip and − 0.9% (IQR − 2.4 to 0.5%) at the spine during continued therapy. Higher levels of bone loss were observed among younger (< 55 years) compared with older (≥ 75 years) women at the hip (− 1.6% vs. − 0.8%) and at the spine (− 1.5% vs. − 0.5%) after AI initiation, and at the hip (− 1.4% vs. − 1.2%) and at the spine (− 2.4% vs. − 0.001%) during continued therapy.

Conclusions

Small but consistent declines in total hip and lumbar spine BMD were present in breast cancer patients following AI therapy initiation or continued AI therapy. Although the overall rates of osteoporosis were low, greater estimated levels of annual bone loss were evident among women < 55 years.

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, American Society of Clinical O (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796. https://doi.org/10.1200/jco.2009.26.3756 CrossRefPubMedPubMedCentral

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509–518. https://doi.org/10.1200/JCO.2009.23.1274 CrossRefPubMed

Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69(1):73–82. https://doi.org/10.1016/j.critrevonc.2008.07.013 CrossRefPubMed

Chien AJ, Goss PE (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24(33):5305–5312. https://doi.org/10.1200/JCO.2006.07.5382 CrossRefPubMed

Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A, Jenkins GD, Carlson EE, Nakamura Y, Schaid DJ, Chapman JA, Shepherd LE, Ellis MJ, Khosla S, Wang L, Weinshilboum RM (2014) Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol 28(10):1740–1751. https://doi.org/10.1210/me.2014-1147 CrossRefPubMedPubMedCentral

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219. https://doi.org/10.1056/NEJMoa1604700 CrossRefPubMedPubMedCentral

Bartsch R, Bergen E (2016) ASCO 2016: highlights in breast cancer. Memo 9(4):211–214. https://doi.org/10.1007/s12254-016-0300-6 CrossRefPubMedPubMedCentral

Kwan ML, Lo JC, Tang L, Laurent CA, Roh JM, Chandra M, Hahn TE, Hong CC, Sucheston-Campbell L, Hershman DL, Quesenberry CP Jr, Ambrosone CB, Kushi LH, Yao S (2014) Bone health history in breast cancer patients on aromatase inhibitors. PLoS ONE 9(10):e111477. https://doi.org/10.1371/journal.pone.0111477 CrossRefPubMedPubMedCentral

Yao S, Zhang Y, Tang L, Roh JM, Laurent CA, Hong CC, Hahn T, Lo JC, Ambrosone CB, Kushi LH, Kwan ML (2017) Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. Breast Cancer Res Treat 161(3):501–513. https://doi.org/10.1007/s10549-016-4068-5 CrossRefPubMed

10.

Lo JC, Kim S, Chandra M, Ettinger B (2016) Applying ethnic-specific bone mineral density T-scores to Chinese women in the USA. Osteoporos Int 27(12):3477–3484. https://doi.org/10.1007/s00198-016-3673-9 CrossRefPubMed

11.

Bonnick S (2010) Bone densitometry in clinical practice. Humana Press, New York. https://doi.org/10.1007/978-1-60327-499-9 CrossRef

12.

Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 international society for clinical densitometry position development conference on bone densitometry. J Clin Densitom 16(4):455–466. https://doi.org/10.1016/j.jocd.2013.08.004 CrossRefPubMed

13.

Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22(12):2546–2555. https://doi.org/10.1093/annonc/mdr017 CrossRefPubMed

14.

Bruyere O, Bergmann P, Cavalier E, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Body JJ (2017) Skeletal health in breast cancer survivors. Maturitas. https://doi.org/10.1016/j.maturitas.2017.08.008

15.

Bainbridge KE, Sowers MF, Crutchfield M, Lin X, Jannausch M, Harlow SD (2002) Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am J Epidemiol 156(5):410–417CrossRefPubMed

16.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlbock M, Jakesz R, Austrian B, Colorectal Cancer Study G (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840–849. https://doi.org/10.1016/s1470-2045(08)70204-3 CrossRefPubMed

Title: Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy
Authors: Marilyn L. Kwan
Song Yao
Cecile A. Laurent
Janise M. Roh
Charles P. Quesenberry Jr.
Lawrence H. Kushi
Joan C. Lo
Publication date: 01-04-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4626-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Analysis of breast cancer in young women in the Department of Defense (DOD) database

Genetic variation in TNFα, PPARγ, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort

PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer

Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work

Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors

Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition

Keynote webinar | Spotlight on antibody–drug conjugates in cancer